Managers / Q1 2026
Sanofi
CIK 0001121404 · 46 AVENUE DE LA GRANDE ARMEE, PARIS, I0, 75017 · 33153774400
Summary
Sanofi reported $336M in U.S.-listed holdings across 9 positions for Q1 2026.
The portfolio is heavily concentrated: Meiragtx alone accounts for 31.4% of reported value.
Compared with Q4 2025, the fund opened 1 new position and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 59.9% · $201M
- Other · 31.4% · $106M
- ADR · 8.7% · $29M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| AGMBAgomab Therapeutics NV | NEW | +2.78M | 2.78M | +$29M | $29M |
| INBXInhibrx Biosciences, Inc. | HELD | +0 | 1.16M | −$14M | $78M |
| NVV1Novavax | HELD | +0 | 6.88M | +$10M | $56M |
| ANABAnaptysBio | HELD | +0 | 821.9K | −$9M | $30M |
| MeiraGTx Holdings plc | HELD | +0 | 12.20M | +$9M | $106M |
| IMRXImmuneering Corp | HELD | +0 | 2.71M | −$4M | $14M |
| MPLTMapLight Therapeutics Inc. | HELD | +0 | 912.0K | +$3M | $19M |
| ELDNEledon | HELD | +0 | 815.0K | +$1M | $3M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2026
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | MeiraGTx Holdings plc | COM | 31.44% | $106M | 12.20M |
| 2 | INBXInhibrx Biosciences, Inc.history → | COM | 23.17% | $78M | 1.16M |
| 3 | NVV1Novavaxhistory → | COM NEW | 16.67% | $56M | 6.88M |
| 4 | ANABAnaptysBiohistory → | COM | 9.04% | $30M | 821.9K |
| 5 | AGMBAgomab Therapeutics NVhistory → | SPONSORED ADS | 8.69% | $29M | 2.78M |
| 6 | MPLTMapLight Therapeutics Inc.history → | COM | 5.52% | $19M | 912.0K |
| 7 | IMRXImmuneering Corphistory → | CLASS A COM | 4.25% | $14M | 2.71M |
| 8 | ELDNEledon | COM | 0.75% | $3M | 815.0K |
| 9 | QTTBQ32 Bio Inc. | COM | 0.47% | $2M | 244.1K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $336M | 9 | May 7, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $310M | 8 | Feb 11, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $260M | 9 | Nov 4, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $176M | 10 | Jul 29, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $166M | 9 | May 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $174M | 9 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.